- Home
- CREV vs SILO Comparison
CREV vs SILO Comparison
Compare CREV & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- SILO
- Stock Information
- Founded
- CREV 2007
- SILO 2010
- Country
- CREV Ireland
- SILO United States
- Employees
- CREV N/A
- SILO N/A
- Industry
- CREV
- SILO Apparel
- Sector
- CREV
- SILO Consumer Discretionary
- Exchange
- CREV Nasdaq
- SILO Nasdaq
- Market Cap
- CREV 6.0M
- SILO 5.9M
- IPO Year
- CREV N/A
- SILO N/A
- Fundamental
- Price
- CREV $4.27
- SILO $0.63
- Analyst Decision
- CREV
- SILO
- Analyst Count
- CREV 0
- SILO 0
- Target Price
- CREV N/A
- SILO N/A
- AVG Volume (30 Days)
- CREV 62.3K
- SILO 354.8K
- Earning Date
- CREV 05-14-2025
- SILO 08-13-2025
- Dividend Yield
- CREV N/A
- SILO N/A
- EPS Growth
- CREV N/A
- SILO N/A
- EPS
- CREV N/A
- SILO N/A
- Revenue
- CREV $39,261,077.00
- SILO $72,102.00
- Revenue This Year
- CREV $40.76
- SILO $1.86
- Revenue Next Year
- CREV $86.18
- SILO N/A
- P/E Ratio
- CREV N/A
- SILO N/A
- Revenue Growth
- CREV 41.52
- SILO N/A
- 52 Week Low
- CREV $2.00
- SILO $0.41
- 52 Week High
- CREV $12.75
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- CREV 49.77
- SILO 45.48
- Support Level
- CREV $4.09
- SILO $0.62
- Resistance Level
- CREV $4.66
- SILO $0.67
- Average True Range (ATR)
- CREV 0.36
- SILO 0.04
- MACD
- CREV -0.06
- SILO -0.01
- Stochastic Oscillator
- CREV 24.41
- SILO 19.92
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.